Article
Microbiology
Alessandra Carattoli, Gabriele Arcari, Giulia Bibbolino, Federica Sacco, Dario Tomolillo, Federica Maria Di Lella, Maria Trancassini, Luigi Faino, Mario Venditti, Guido Antonelli, Giammarco Raponi
Summary: A study conducted in a university hospital in Rome, Italy identified multiple CZA-resistant KPC-3 protein variants, including novel variants that had not been reported before. These variants showed different sensitivities and activities to antibiotics, possibly due to mutations caused by amino acid substitutions, insertions, and deletions.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Laura Campogiani, Pietro Vitale, Alessandra Lodi, Alessandra Imeneo, Carla Fontana, Cartesio D'Agostini, Mirko Compagno, Luigi Coppola, Ilaria Spalliera, Vincenzo Malagnino, Elisabetta Teti, Marco Iannetta, Massimo Andreoni, Loredana Sarmati
Summary: This study aimed to collect and describe real-life data on CAZ-AVI-resistant Klebsiella pneumoniae isolates in a University Hospital. The results showed that prior use of CAZ-AVI was associated with the emergence of drug resistance.
Article
Microbiology
Chunlei Wang, Jiankang Zhao, Zhibo Liu, Aihua Sun, Lingxiao Sun, Binbin Li, Binghuai Lu, Yingmei Liu, Bin Cao
Summary: This study describes the in vivo evolution of carbapenem and ceftazidime-avibactam resistance in a pneumonia patient by analyzing four longitudinal Klebsiella pneumoniae clinical isolates. The results showed a dynamic change of resistance phenotype and the emergence of resistance to ceftazidime-avibactam and carbapenems.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Infectious Diseases
Ke Ma, Yu Feng, Zhiyong Zong
Summary: Aztreonam/avibactam has additional coverage for metallo-beta-lactamases compared with ceftazidime/avibactam, but some strains may develop resistance to aztreonam/avibactam while remaining susceptible to ceftazidime/avibactam.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2022)
Article
Infectious Diseases
J. Guzman-Puche, E. Perez-Nadales, M. Perez-Vazquez, M. Causse, I Gracia-Ahufinger, A. Mendez-Natera, Y. Allalou-Ruiz, C. Elias, J. Oteo-Iglesias, J. Torre-Cisneros, L. Martinez-Martinez
Summary: This study describes the emergence of CZA resistance in clinical isolates, which is related to mutations in the bla(KPC) gene. The study identifies new alleles, KPC-94 and KPC-95, that do not cause carbapenem resistance.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2022)
Article
Infectious Diseases
Carolina Venditti, Ornella Butera, Marcello Meledandri, Maria Pia Balice, Giulio Cesare Cocciolillo, Carla Fontana, Silvia D'Arezzo, Chiara De Giuli, Mario Antonini, Alessandro Capone, Francesco Messina, Carla Nisii, Antonino Di Caro
Summary: The study analyzed ceftazidime-avibactam-resistant KPC-producing Klebsiella pneumoniae strains collected from 31 patients in six hospitals in Rome, revealing mutations in KPC variants within the bla(KPC-3) gene and the presence of high-risk clones (ST512, 101, and 307). The findings highlight concerns over the potential selection of a multidrug-resistant phenotype in strains showing resistance to both ceftazidime-avibactam and carbapenems.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Microbiology
Yanqin Huang, Karol Sokolowski, Amisha Rana, Nidhi Singh, Jiping Wang, Ke Chen, Yinzhi Lang, Jieqiang Zhou, Neera Kadiyala, Fiorella Krapp, Egon A. Ozer, Alan R. Hauser, Jian Li, Jurgen B. Bulitta, Zackery P. Bulman
Summary: Combining aminoglycosides with ceftazidime/avibactam shows promising synergy against KPC-producing Klebsiella pneumoniae infections, leading to reduced bacterial counts. Selecting aminoglycosides based on genes or susceptibilities can enhance the pharmacodynamic activity of the combination therapy.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Lin Wang, Weiyi Shen, Rong Zhang, Jiachang Cai
Summary: This study identified a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in a Citrobacter koseri isolated from a patient in a Chinese hospital. The KPC-123 variant showed high-level resistance to ceftazidime and ceftazidime/avibactam, but remained susceptible to carbapenems. Whole-genome sequencing and genomic analysis revealed the transfer and in vivo evolution of the bla(KPC)-carrying plasmid. Active surveillance is needed to prevent and control the dissemination of ceftazidime/avibactam resistance.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Microbiology
Xiangning Huang, Siquan Shen, Fan Chang, Xin Liu, Jinxi Yue, Ning Xie, Lin Yin, Fupin Hu, Daiwen Xiao
Summary: The emergence of new KPC variants leading to treatment failure with ceftazidime-avibactam presents a new challenge for clinical anti-infection treatment. In this study, a ceftazidime-avibactam-resistant K. pneumoniae strain carrying a novel KPC-134 variant was reported. The study highlights the importance of timely identification of KPC variants and effective anti-infective therapy for saving infected patients.
MICROBIOLOGY SPECTRUM
(2023)
Article
Immunology
Yili Chen, Runshi Yang, Penghao Guo, Pingjuan Liu, Jiankai Deng, Zhongwen Wu, Qingping Wu, Junqi Huang, Kang Liao
Summary: This study reports the first case of CZA resistance caused by bla(KPC-145) emerging during treatment of K. pneumoniae infection associated with bla(KPC-2) in China. Routine testing for antibiotic susceptibility and carbapenemase genotype is essential during CZA treatment.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Microbiology
Agnes B. Jousset, Saoussen Oueslati, Cecile Emeraud, Remy A. Bonnin, Laurent Dortet, Bogdan I. Iorga, Thierry Naas
Summary: Resistance to the combination of ceftazidime (CAZ) and avibactam (AVI) is increasing, with a CAZ-AVI-resistant Klebsiella pneumoniae strain reported here. This strain, belonging to the high-risk sequence type 307 (ST307) clone, produces Klebsiella pneumoniae carbapenemase 39 (KPC-39), a single-amino-acid variant of KPC3. The study found that KPC-39 has lost carbapenemase activity but shows increased affinity for CAZ, suggesting potential silent dissemination in European healthcare settings.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Vincenzo Di Pilato, Noemi Aiezza, Valentina Viaggi, Alberto Antonelli, Luigi Principe, Tommaso Giani, Francesco Luzzaro, Gian Maria Rossolini
Summary: This study characterized a Klebsiella pneumoniae isolate with high-level resistance to ceftazidime-avibactam due to the presence of KPC-53, a variant of KPC-3 with unique genetic features. Whole-genome sequencing revealed the presence of two copies of blaKPC-53 on different plasmids, shedding light on the mechanisms of resistance to ceftazidime-avibactam.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Yanqin Huang, Tiffany Wu, Omar Perez, Amisha P. Rana, Liang Chen, Barry N. Kreiswirth, Michael J. Satlin, Zackery P. Bulman
Summary: Ceftazidime/avibactam is an important treatment option for infections caused by KPC-Kp, but resistance can emerge during treatment. The study aimed to define the concentrations required to suppress regrowth in ceftazidime/avibactam susceptible isolates and identify active therapies against ceftazidime/avibactam-resistant KPC-Kp.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Zackery P. Bulman, Xing Tan, Ting-Yu Chu, Yanqin Huang, Amisha P. Rana, Nidhi Singh, Stephanie A. Flowers, Yasuhiro Kyono, Barry N. Kreiswirth, Liang Chen
Summary: The combination of carbapenem resistance and hypervirulence in Klebsiella pneumoniae poses an emerging and urgent threat. Transcriptomic analysis suggests that altered transcription of multiple key pathways contributes to antibiotic tolerance in carbapenem-resistant K. pneumoniae with hypervirulence plasmids.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2022)
Article
Infectious Diseases
Charalampos Zarras, Elias Iosifidis, Maria Simitsopoulou, Styliani Pappa, Angeliki Kontou, Emmanuel Roilides, Anna Papa
Summary: This article reports a case of neonatal sepsis caused by CAZ/AVI-resistant bla(KPC-2)-harboring Klebsiella pneumoniae carrying bla(VEB-25), and describes the use of a customized active surveillance program and enhanced infection control measures. The emergence of bla(VEB-25) signals horizontal plasmid transfer in hospital facilities and highlights the importance of monitoring for novel resistance mechanisms. Molecular diagnostics can guide appropriate antimicrobial therapy and the early implementation of infection control measures against antimicrobial resistance.
Article
Microbiology
Otavio Hallal Ferreira Raro, Patrice Nordmann, Manuel Dominguez Pino, Jacqueline Findlay, Laurent Poirel
Summary: There is an increasing occurrence of multidrug-resistant (MDR) and hypervirulent (hv) Klebsiella pneumoniae (MDR-hvKp) convergent clones. These strains can cause difficult-to-treat infections and have a higher mortality rate in healthy adults. This study in Switzerland identified a rate of 9.0% K. pneumoniae with a virulence genotype, producing carbapenemase and recovered from rectal swabs, urine, and blood. The presence of alarming MDR-hvKp and MDR nonhypervirulent K. pneumoniae (MDR-nhv-Kp) isolates highlights the need for surveillance networks to track and monitor their spread.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Jacqueline Findlay, Laurent Poirel, Maxime Bouvier, Valeria Gaia, Patrice Nordmann
Summary: Carbapenem-resistant Enterobacterales, including KPC-producing Klebsiella pneumoniae, pose a major threat to public health due to their rapid spread. Ceftazidime-avibactam, a beta-lactam/beta-lactamase inhibitor combination, has shown excellent activity against multidrug-resistant KPC-producing Enterobacterales strains. However, there is an increasing occurrence of CAZ-AVI-resistant K. pneumoniae isolates, mainly due to the emergence of KPC variants that confer resistance to CAZ-AVI but retain carbapenem resistance.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Letter
Infectious Diseases
Jacqueline Findlay, Juan Bosch Duran, Laurent Poirel, Patrice Nordmann
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2023)
Article
Microbiology
Samanta Freire, Teresa Grilo, Bruna Rodrigues, Rui Oliveira, Carla Esteves, Antonio Marques, Laurent Poirel, Marta Aires-de-Sousa
Summary: This study aimed to analyze the occurrence and characteristics of ESBL- and carbapenemase-producing E. coli among bivalves. Out of 522 collected bivalve samples, E. coli growth was observed in 39% of the samples. Nine samples (4.4%) were contaminated with ESBL producers and one sample (0.5%) was contaminated with a carbapenemase-producing K. pneumoniae. The presence of ESBL- and carbapenemase-producing Enterobacteriaceae in bivalves indicates that the marine environment could be a reservoir of critical bacterial pathogens, posing a potential risk to human health.
Article
Infectious Diseases
Maxime Bouvier, Auriane Kerbol, Jacqueline Findlay, Samanta Freire, Laurent Poirel, Patrice Nordmann
Summary: Resist Acineto is a novel immunochromatographic test for detecting the major acquired carbapenemases (OXA-23, OXA-40, OXA-58, and NDM) in Acinetobacter spp. This test is rapid and easy to perform, and it has shown excellent specificity and sensitivity with 100% positive and negative predictive values in both cases.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
(2023)
Article
Infectious Diseases
Jacqueline Findlay, Patrice Nordmann, Maxime Bouvier, Auriane Kerbol, Laurent Poirel
Summary: This study investigated the spread and emergence of A. baumannii clones co-producing OXA-23 and ArmA in Switzerland. The majority of the isolates were obtained from infections and belonged to the high-risk GC-2 clone. Monitoring and control of these MDR A. baumannii strains are crucial to prevent further spread.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Otavio Hallal Ferreira Raro, Maxime Bouvier, Auriane Kerbol, Jean-Winoc Decousser, Laurent Poirel, Patrice Nordmann
Summary: The study developed a rapid test for the detection of Acinetobacter baumannii susceptibility to the antibiotic cefiderocol. The test showed high sensitivity and specificity and significantly reduced the time required compared to current methods.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Patrice Nordmann, Maxime Bouvier, Laurent Poirel
Summary: Carbapenemase-producing Enterobacterales (CPE) are a major health concern globally, with limited therapeutic options in Switzerland. This study evaluated the susceptibility of CPE isolates recovered in Switzerland from 2018 to 2020 to novel β-lactam/β-lactamase inhibitor combinations, including ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam. The majority of clinical CPE isolates were Klebsiella pneumoniae and Escherichia coli, and the distribution of carbapenemases varied. The study found that meropenem-vaborbactam had the highest susceptibility among the three combinations, followed by ceftazidime-avibactam and imipenem-relebactam. These findings can help optimize first-line therapy for CPE infections.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Christophe Le Terrier, Patrice Nordmann, Chloe Buchs, Doris Yoong Wen Di, Gian Maria Rossolini, Roger Stephan, Mariana Castanheira, Laurent Poirel
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Teresa Grilo, Samanta Freire, Bruno Miguel, Luis Nogueira Martins, Maria Favila Menezes, Patrice Nordmann, Laurent Poirel, Maria Jose Rego Sousa, Marta Aires-de-Sousa
Summary: This study evaluated the occurrence of plasmid-mediated fos genes among fosfomycin-resistant Escherichia coli isolates collected from patients in Lisbon, Portugal. The results showed a low prevalence of fosfomycin-resistant E. coli isolates, but 15% of these isolates carried transferable fosA genes, and a high rate of extended-spectrum beta-lactamase (ESBL) production was observed.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2023)
Article
Microbiology
Niklas Kroemer, Lisa F. Amann, Aneeq Farooq, Christoph Pfaffendorf, Miklas Martens, Jean-Winoc Decousser, Nicolas Gregoire, Patrice Nordmann, Sebastian G. Wicha
Summary: Rational combination therapy can increase efficacy and prevent the emergence of resistance. This study found that the combination of ceftazidime/avibactam and fosfomycin showed strong synergy in suppressing bacterial count and preventing resistance. Clinical evaluations are needed to explore dose reductions and the use of this combination for highly resistant strains.
MICROBIOLOGY SPECTRUM
(2023)
Article
Infectious Diseases
Jacqueline Findlay, Roberto Sierra, Otavio Hallal Ferreira Raro, Marta Aires-de-Sousa, Diego O. Andrey, Patrice Nordmann
Summary: This study analysed a collection of E. coli strains harbouring acquired fosA genes and found high-level resistance to fosfomycin. The strains also carried other antibiotic resistance genes and were capable of transmission through conjugation.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2023)
Article
Infectious Diseases
Valentina Dona, Patrice Nordmann, Sonja Kittl, Simone Schuller, Maxime Bouvier, Laurent Poirel, Andrea Endimiani, Vincent Perreten
Summary: A study in Switzerland found that Enterobacter hormaechei producing the carbapenemase OXA-48 was identified in companion animals and human patients. The study analyzed the genetic relatedness of these strains and their mobile genetic elements and found a connection between antimicrobial resistance in E. hormaechei and animals and humans in the same environment.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)